Mesenchymal Stem Cell Composition for Schwann Cell Remyelination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating Charcot-Marie-Tooth disease, particularly those involving mesenchymal stem cells, are limited by restrictive differentiation and proliferation potencies, requiring complex procedures and donor matching, while existing treatments for autosomal dominant cases are inadequate due to gain-of-function mutations.
Innovation Solution
A pharmaceutical composition containing mesenchymal stem cells or insulin secreted from these cells is developed to promote Schwann cell proliferation, thereby restoring myelination and treating Charcot-Marie-Tooth disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bone marrow mesenchymal stem cells are used for treatment, then therapeutic effect is achieved, but the procedure becomes complex and requires donor matching
Solution Approach 1:
The patent uses an extracellular matrix (ECM) as an intermediary carrier to deliver mesenchymal stem cells. The ECM provides a three-dimensional structure that supports cell survival, proliferation, and differentiation while simplifying the transplantation procedure. This mediator approach eliminates the need for complex donor matching procedures while maintaining therapeutic efficacy, as the ECM protects and guides the stem cells to the target tissue.
Solution Approach 2:
The patent employs preliminary culturing of mesenchymal stem cells in the extracellular matrix before transplantation. This pre-preparation allows the cells to be activated and conditioned in advance, enhancing their therapeutic potential while simplifying the actual transplantation procedure. The cells are pre-loaded into the ECM structure, ready for direct implantation without complex surgical procedures.
2Adaptability or versatility
If bone marrow mesenchymal stem cells are used, then treatment is possible, but differentiation and proliferation potencies are limited
Solution Approach 1:
The patent changes the physical and chemical parameters of the cell culture environment by using an extracellular matrix with specific structural properties. The ECM provides appropriate stiffness, porosity, and biochemical cues that enhance both the differentiation capacity and proliferation potency of mesenchymal stem cells. This parameter optimization allows the cells to maintain high proliferative activity while acquiring enhanced differentiation capabilities toward neural lineages.
Solution Approach 2:
The patent creates a composite system combining mesenchymal stem cells with extracellular matrix materials. This composite structure provides both the biological activity of living cells and the structural support of the matrix, resulting in enhanced differentiation and proliferation potentials that neither component achieves alone. The ECM acts as a scaffold that amplifies the therapeutic capabilities of the stem cells.
3Ease of operation
If umbilical cord mesenchymal stem cells are used, then cell collection is simplified, but inhibition of muscle cell death has not been reported
Solution Approach 1:
The patent uses extracellular matrix as an intermediary to enhance the therapeutic efficacy of umbilical cord mesenchymal stem cells. The ECM provides a protective and supportive environment that enables these cells to effectively inhibit muscle cell death, a capability that has not been observed in previous studies. The matrix mediates the interaction between the stem cells and target tissues, unlocking therapeutic potential that remains dormant in conventional delivery methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively prevents or treats Charcot-Marie-Tooth disease by enhancing Schwann cell proliferation and myelination, offering a mechanism for restoring nerve function.
Implementation Method 1
Mesenchymal stem cells, which are stromal origin cells with self-renewal capacity, can differentiate into bone, cartilage, adipose tissue, muscle, tendon, ligament, nervous tissue
Implementation Method 2
pharmaceutical composition containing mesenchymal stem cells or insulin secreted from mesenchymal stem cells for preventing or treating Charcot-Marie-Tooth disease
Data Source
AI summary
The present invention relates to a pharmaceutical composition, for preventing or treating Charcot-Marie-Tooth disorder, comprising mesenchymal stem cells or insulin secreted by mesenchymal stem cells.